Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 143.00 151.00 170.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 457

Amryt Pharma Share Discussion Threads

Showing 4826 to 4844 of 7300 messages
Chat Pages: Latest  196  195  194  193  192  191  190  189  188  187  186  185  Older
See Astra zenica bought a priority review voucher for $95m (down from some years ago). Don't AMYT have one of these if ap101 gets approval?
hxxps:// Acromegaly Drug Market Top Competitors are Silence Therapeutic, Strongbridge Biopharma plc, Amryt Pharma plc, Foresee Pharmaceuticals Co., Ltd, Ipsen Pharma and Others Acromegaly is a rare hormonal disorder also known as gigantism. It occurs when pituitary gland releases excessive growth hormone in the body due to the tumor formation in the pituitary gland. This abnormal production of growth hormone results in the bone enlargement. It mainly affects the geriatric population. Global Acromegaly Drug Market is rising gradually with a substantial CAGR of 5.10% in the forecast period of 2019-2026. This rise in market value can be attributed in increase in awareness and concerns regarding the health of patients, increasing prevalence of growth hormone disorders and high expenditure in healthcare sector.
Well no new update from AMYT since the result of the AGM RNS dated 10th July. Will this drag into 2020 before AMYT relists? From my previous experience of AIM listed companies (including AMYT) they almost always never stick to the initial timetables.
Yes Bermuda I heard of Amryt through Debra Ireland a few years ago. An excellent charity.
DEBRA of America is a high profile Epidermolysis Bullosa medical research charity and they will be hosting their annual benefit evening in New York in October. Amryt is one of three companies (& the only non US one) being recognised with a Partners in Progress award to be presented on the night. Good stuff and well done Amryt. Https://
Hi Chica1....As per Newton’s Third Law - Every action has an equal and opposite reaction. Put simply, I have been on this site long enough to realise that Papillon is usually reacting to others comments, rather than irritating others as his primary objective. As for yourself, all the best with the medical condition which afflicts your family. EB is a nasty disease. Previous trials with episalvan have shown a 10% improvement in the skin healing; I would doubt that you would be able to notice significant improvement in a single participant study!
Yes Papillon everyone is anonymous here.I see from you recent posting that you seem to irritate people on every forum you partake in. Quite sad actually that these boards seem to be your only life!
mdalos1 6 Aug '19 - 19:41 - 4702 of 4702 0 0 0 LOLs... absolutely clueless !! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Don't keep beating yourself up, MADLOSS! PMSL ROFLMAO
As soon as the admission document was published FAST returned from suspension on the 31st March 2016 The acquisition of AMYT (an RTO) didn't become effective until 18th April 2016 when the company named changed to Amryt Pharma. Hence it's possible that AMYT could relist as soon the admission document is published in "early August" and before the Aegerion deal is finalised. Will it? No idea.
Thanks. Going to be interesting. Not a bad thing being suspended anyhow given the markets.
Readmission doc due to be published in early Aug, readmission to trading planned for "early Q4"
I've forgotten. What's the potential timetable re the merger?
Any day now
You are, chica1, like the rest of us an anonymous poster so I have no idea whether you are telling the truth, or not. I must admit to finding it strange that one who does "not own any stocks" should be posting on a bb of a site, ADVFN, that caters solely for private investors. I'm surprised you even bothered to look for the site. Of course you are entitled to your opinion and if you are telling the truth and have found, in your experience, that Episalvan is not that effective (if at all) you might be the exception that proves the rule. After all that's no doubt why AMYT had to increase the size of the phase III trial and increase the patient numbers. I doubt if there is any drug, or treatment, currently on sale that is effective for every patient. We'll have to await the final phase III results to find out whether your experiences (if you are being truthful) with Episalvan are the exception, or the norm!
mdalos1 31 Jul '19 - 00:19 - 4692 of 4693 0 0 0 POT KETTLE.... 100s of posts on here almost all of the time, relentlessly at times, including copy/pasting other people's posts AND having "arguments" here with Posters on an entirely different BB !!!! How ironic... LOLs Do you think you'll be down 65% or maybe as much as 75% when the dust settles ? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> ROFLMAO. PMSL. I thought I'd copy your words of wisdom (LOL) for posterity before you delete them! I make no prediction of the likely share price when they relist, MADLOSS, unlike you! You have nailed your colours to the mast. When they relist I can refer to this post to see if you were right, or wrong! PS. Every time I post on this bb, you follow suit, MADLOSS. Are you stalking me? If you want to get to know me better just post me a message and we can arrange to meet up somewhere. We can then have a little chat! Close up and personal! LOL
I do not own any stocks. I am probably here for selfish reasons in the hope of relief for the condition that afflicts my family.
PMSL. ROFLMAO. Okay, chica1. We've got the message! So you're doing your own single patient AP101 phase III trial. It's a shame that AMYT are conducting a phase III AP101 trial with circa 200 patients in different locations. How very wasteful of AMYT. They could have done a single patient phase III trial like yours and saved a fortune! PMSL ROFLMAO. 16 posts since you joined ADVFN in February of this year. All negative and all on AMYT. Don't you have any interest in other shares? How very strange!
Got our hands on some Episalvan again. Skin conditions tend to flair up in hot an clammy weather. We're not seeing ground breaking results.
RNS targets early Q4 for re admission to AIM
Chat Pages: Latest  196  195  194  193  192  191  190  189  188  187  186  185  Older
ADVFN Advertorial
Your Recent History
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221007 22:42:52